Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for PuriBlood Medical Co's Net Margin % or its related term are showing as below:
ROCO:6847'
s Net Margin % Range Over the Past 10 Years
Min: -731.05 Med: -44.28 Max: 12.03
Current: -47.37
ROCO:6847's Net Margin % is ranked worse than 74.88% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.81
vs ROCO:6847: -47.37
PuriBlood Medical Co (ROCO:6847) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
PuriBlood Medical Co Net Margin % Related Terms
PuriBlood Medical Co Net Margin % Historical Data
* Premium members only.
The historical data trend for PuriBlood Medical Co's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6847 vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, PuriBlood Medical Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PuriBlood Medical Co Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PuriBlood Medical Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where PuriBlood Medical Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PuriBlood Medical Co (ROCO:6847) has a Net Margin % of -58.17% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on PuriBlood Medical Co and its competitors. According to the industry distribution chart, PuriBlood Medical Co ranks #152 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 74.9%.
Is PuriBlood Medical Co's Net Margin % too high?
PuriBlood Medical Co's current Net Margin % is -58.17%. Based on the distribution chart, PuriBlood Medical Co ranks #152 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, PuriBlood Medical Co has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PuriBlood Medical Co's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PuriBlood Medical Co ranks #152 out of 203 companies for Net Margin %. This places PuriBlood Medical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on PuriBlood Medical Co and its competitors. PuriBlood Medical Co's current Net Margin % is -58.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuriBlood Medical Co stock overvalued right now?
Based on GuruFocus' analysis, PuriBlood Medical Co (ROCO:6847) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$66.17, compared to a current price of NT$77.70 — trading 17.4% above its estimated fair value. The current Net Margin % is -58.17%. PuriBlood Medical Co's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For PuriBlood Medical Co (ROCO:6847), the current Net Margin % is -58.17% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PuriBlood Medical Co (ROCO:6847) Overvalued in 2026?
Based on GuruFocus' analysis, PuriBlood Medical Co stock appears to be overvalued.
The current stock price of NT$77.70 is trading 17.4% above its estimated GF Value™ of NT$66.17.
GuruFocus considers PuriBlood Medical Co to be Modestly Overvalued.
Key valuation signals for ROCO:6847:
Net Margin %: -58.17%
GF Value™: NT$66.17 vs. price of NT$77.70 (17.4% above fair value)
No single metric tells the full story. See the ROCO:6847 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PuriBlood Medical Co Ltd is engaged in developing solutions for leukoreduction, cell separation, and anti-fouling materials. Its technology protects to supports living beings from medical devices to daily protection. The products of the company include Leukoreduction, Cell Separation, and P-tex.
74GF Score
Get the complete analysis for ROCO:6847
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6847 has been successfully added to your 
